Sometime soon, if all goes well, we'll have four or even five approved vaccines for Covid-19. Do they work differently? Is there a "best" one, and will some Canadians hold out for that brand? How many eligible people are opting out of the early doses? Are reports of allergic reactions and even deaths following vaccination worth worrying about? And what happens when rich people try to jump the queue?

GUEST: Sabina Vohra-Miller, masters in clinical pharmacology, co-founder of the Vohra Miller Foundation

We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:

Through email at [email protected] 

Or @thebigstory.bsky.social on Bluesky